-
Interim NADIM ADJUVANT Data Suggest Adjuvant Chemo-IO May Reduce Recurrence Risk in Patients Following Complete Resection
-
Final FLAURA2 OS Data Show Osimertinib Plus Chemo Offers Benefit Compared with Monotherapy
-
Potential Impact of GLP1-RAs on TKI-induced Weight Gain in Patients with NSCLC
-
No “Known” Risk Factors: The Health Consequences of Radiation Therapy
-
Discussion Covered Updates, Strategies, and Controversies in Lung Cancer Staging
-
No PFS, OS Benefit Seen in Final Results from PACIFIC-2
-
WCLC Attendees Hear Preview of Proposed Changes for the 9th Edition of the TNM Staging Classification for Thoracic Cancers
-
Treatment of Immunotherapy-Related Dermatologic Toxicities: An Interview with Dr. Mario Lacouture
-
A Holistic Approach to Patient Care
Targeted Therapies
-
Toward Durable Disease Control in EGFR-Mutant (mt) NSCLC: Interpreting the Survival Signals from FLAURA2 and MARIPOSA
While the FLAURA2 and MARIPOSA trials represent a defining step toward durable disease control in EGFR mt (+) NSCLC, Drs. Ilit Turgeman and Pasi A. Jänne emphasize that further advances will depend on understanding what persists after an initial response.
-
Research Points to Translational Path Toward Precision Immunotherapies for EGFR-Mutant NSCLC
Dr. Yongfeng He said recent data show EGFR-L858R to be a shared, druggable neoantigen and provide a compelling rationale for the development of mutation-directed immunotherapies.
-
Under Therapeutic Pressure: ELCC Session Highlights How Tumor Switching is Reshaping the Treatment Landscape
Experts emphasize the need for multidisciplinary approaches, personalized therapies, and strategies to address intratumor heterogeneity.
-
Keynote Address Explores the Future of Biomarkers in the ADC Era
During his lecture at the 2026 European Lung Cancer Congress, Dr. Fred R. Hirsch outlined the current state of knowledge in ADC research, as well as what still needs to be learned.
-
Final Results From the ETOP ADEPPT Trial Show Promise for Two Underrepresented Patient Populations
The findings, presented by Dr. Jarushka Naidoo at ELCC 2026, demonstrated that treatment with adagrasib was effective in fit patients aged 70 years and older with KRAS G12C-mutant NSCLC and provided quality-of-life benefits for those with poor performance status.
-
Personalized Lung Cancer Therapies: One Size Does Not Fit All
During the TTLC 2026 Opening Keynote, Dr. John V. Heymach said personalizing lung cancer therapies will require disentangling heterogeneity to understand the underlying factors driving the disease in each patient.
-
Debate Centers on Whether RAS Inhibitors Will Become First-Line Therapy by 2026
Drs. Ferdinandos Skoulidis and Marina C. Garassino went head-to-head over whether emerging KRAS combination data support first-line adoption by year’s end.
-
Research to Watch: Aumolertinib Delivers Notable Performance as an EGFR-Targeted Therapy in the Adjuvant Setting
Results from the phase III ARTS trial illustrate the potential of aumolertinib as adjuvant therapy for patients with resected EGFR-mutated NSCLC.
-
The Power of Team-Based Science
After being awarded the $2.5 million IASLC-LCRF grant, ILCN follows up with the research progress of Dr. David Barbie and his international team of investigators.
-
Targeting NRG1 Fusions: A Potential Role for Zenocutuzumab as a First-Line Therapeutic Option
Dr. Stephen Liu recently highlighted the safety and efficacy of a targeted therapy for patients with NRG1-positive cancers with updated data from the ongoing eNRGy trial.